A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-Muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Sunitinib (Primary) ; BCG
- Indications Bladder cancer; Urethral cancer
- Focus Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 30 Jan 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 19 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.